PDF(Pubmed)
Abstract：
The immunopathogenesis of HS is partially understood and exhibits features of an autoinflammatory disease; it is associated with the potential involvement of B cells and the contribution of Th1 or Th17 cell subsets. Recently, the pathogenic role of both innate immunity and IL-1 family cytokines in HS has been deeply investigated. Several agents targeting the IL-1 family pathway at different levels are currently available and under investigation for the treatment of HS. HS is still characterized by unmet clinical needs and represents an expanding field in the current scientific research. The aim of this narrative review is to describe the pathological dysregulation of IL-1 family members in HS and to provide an update on therapeutic strategies targeting IL-1 family cytokine signaling. Further clinical and preclinical data may likely lead to the enrichment of the therapeutic armamentarium of HS with IL-1 family cytokine antagonists.
摘要：
HS的免疫发病机制已得到部分理解，并表现出自身炎性疾病的特征；它与B细胞的潜在参与以及Th1或Th17细胞亚群的贡献有关。最近,已经深入研究了先天免疫和IL-1家族细胞因子在HS中的致病作用。目前有几种不同水平靶向IL-1家族途径的药物可用于治疗HS，并正在研究中。HS的特征仍然是未满足的临床需求，并且代表了当前科学研究中不断扩大的领域。这篇叙述性综述的目的是描述HS中IL-1家族成员的病理失调，并提供针对IL-1家族细胞因子信号传导的治疗策略的更新。进一步的临床和临床前数据可能导致具有IL-1家族细胞因子拮抗剂的HS治疗性存储器的富集。
